H1B Salary Data

Home › Employers › Novadoz Pharmaceuticals LLC

Novadoz Pharmaceuticals LLC: H-1B salaries and sponsorship

Novadoz Pharmaceuticals LLC filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 4. Median offered salary: $69,098.

Applications (LCAs)4
Certified4
Employer addressPiscataway, NJ
H-1B dependent employerNo
Median offered salary$69,098
Middle half of salaries$65,307–$97,134
10th–90th percentile$62,227–$143,853

Does Novadoz Pharmaceuticals LLC sponsor H-1B visas?

Novadoz Pharmaceuticals LLC filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on May 13, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Analyst2$63,596
Director, Supply Chain1$175,000
Operations Research Analyst1$71,178

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20231$175,000
FY20252$63,596
FY20261$71,178

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Operations Research Analyst$71,178
Level I
Trenton, NJMay 13, 2026Oct 1, 2026Certified
Analyst$60,174
Level I
Piscataway, NJJun 13, 2025Oct 1, 2025Certified
Analyst$67,018
Level I
Piscataway, NJJun 13, 2025Oct 1, 2025Certified
Director, Supply Chain$175,000
Level IV
Piscataway, NJSep 14, 2023Sep 27, 2023Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).